News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
TipRanks Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article provides an earnings forecast for Ascentage Pharma Group International (AAPG), highlighting that 9 analysts currently recommend a "Buy" rating with a target price indicating a significant upside. The report includes current stock performance and a peer comparison, but notes that specific financial …
This article compiles recent news and updates concerning Ascentage Pharma Group International - Unsponsored ADR (AAPG). Several reports from Zacks and MarketBeat highlight Wall Street analysts' predictions of significant upside potential for AAPG, ranging from 152.23% to 160.09%. Other news items cover fluctuations in …
Ascentage Pharma Group International (AAPG) has announced a board meeting scheduled for August 19, 2026. The main purpose of this meeting is to review and approve the company's unaudited interim results for the six months ending June 30, 2026, and to authorize their publication. …
Ascentage Pharma Group International has issued a correction regarding the timing of its 2026 Six Month Interim Results announcement and corporate update. The event will now take place at 7:00 am Eastern Daylight Time (EDT) on August 19, 2026, with an English language webcast …
Ascentage Pharma announced it will release its unaudited six-month 2026 interim results and provide a corporate update on August 19, 2026, at 7:00 am EDT / 7:00 pm HKT. The company will host a Mandarin investor webcast on August 19, 2026, and an English …
Ascentage Pharma Group International has appointed Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer to bolster its global expansion strategy. Dr. Miyara will lead global business development, while Mr. Ziegler will manage commercialization in the United States and …
Ascentage Pharma has announced the appointments of Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer. These appointments aim to strengthen the company's global business development and establish a dedicated commercial organization in the United States. Both executives will …
Ascentage Pharma Group International Co., Ltd. (6855) has approximately 760 employees worldwide as of March 2026, marking a 19.2% growth since 2023. The company, headquartered in Suzhou, China, with major operations in China and the United States, is actively hiring, with 5 active job …
Ascentage Pharma Group International (HKEX:6855) generated 638.92 million HKD last year, with its top-performing segment, Therapies for Hematological Malignancies, contributing 541.47 million HKD. The majority of this revenue, 622.65 million HKD, came from China. The article provides a breakdown of the company's revenue by …
Ascentage Pharma's Chairman and CEO, Dr. Dajun Yang, has been recognized on The Medicine Maker Power List 2026, ranking No. 3 in the Small Molecules category. The list honors 60 global leaders driving innovation in drug discovery and development. Dr. Yang's inclusion highlights his …
This article provides a technical analysis of Ascentage Pharma Group International (AAPG), covering key indicators and moving averages. It details the current signals for MACD, RSI, KDJ, and others, showing a mix of neutral and sell signals, alongside various moving average values. The analysis …
This article provides an overview of Ascentage Pharma Group International (AAPG), detailing its current stock price, market capitalization, and recent trading activity. It highlights the company's financial information, discussions, and analysis resources available on TradingKey, and emphasizes the general nature of the investment information …
This article provides key financial insights into Ascentage Pharma Group International (AAPG) through its income statement, offering both quarterly and annual data. It includes FAQs explaining how to interpret the income statement, distinguishing between quarterly and annual reports, and identifying the most critical metrics …
Ascentage Pharma Group International - Unsponsored ADR (AAPG) closed the last trading session at $18.29, gaining 9.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any …
This article provides an overview of Ascentage Pharma Group International's (AAPG) cash flow, detailing its operating, investing, and financing activities. It explains what each type of cash flow represents and how much the company generated or used in recent fiscal periods. Key financial figures …
This article provides a financial summary of Ascentage Pharma Group International (AAPG), highlighting its stock price, market capitalization, and upcoming earnings report. It emphasizes the availability of financial analysis tools on TradingKey, allowing investors to review income statements, balance sheets, and cash flow statements. …
Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, has been named to The Medicine Maker Power List 2026, ranking No. 3 in the Small Molecules category among 60 global pharmaceutical leaders. The recognition highlights his leadership in developing a small-molecule oncology pipeline, including …
Ascentage Pharma Group International (NASDAQ:AAPG) experienced a significant 87.2% decline in short interest during July, falling to 20,246 shares as of July 15th. Despite this reduction, analysts maintain a bullish outlook with a consensus "Buy" rating and an average price target of $46.43, even …
Ascentage Pharma Group International (NASDAQ:AAPG) shares gapped down prior to trading on Friday, opening at $18.52 after closing at $19.33, and later trading around $18.07. Despite this dip, Wall Street analysts maintain a bullish outlook with a consensus "Buy" rating and a price target …
Ascentage Pharma Group International (AAPG) is a clinical-stage biotechnology company focused on cancer, chronic hepatitis B, and age-related diseases, showing potential for significant growth. Analysts project a potential upside of 158.88% despite the company currently being in a developmental phase with negative earnings and …
Ascentage Pharma Group International has established a $200 million At-The-Market (ATM) offering program on Nasdaq. The biopharmaceutical company filed a shelf registration statement with the SEC to enable flexible capital raising in the U.S. market through the sale of American depositary shares. This move …
Ascentage Pharma Group International plans an at-the-market (ATM) equity program to sell up to US$200 million in American depositary shares (ADSs) on Nasdaq through Citigroup, Deutsche Bank, and BTIG. The proceeds are intended to fund research and development, clinical trials, commercialization, and general corporate …
Search by ticker symbol or company name and select a result to open its chart.